0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Cell > APP > CHEK-ATP081

HEK293/Human APP (GFP) Stable Cell Line

Order Now

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    HEK293/Human APP (GFP) Stable Cell Line
  • Application

    Screening β-secretase and γ-secretase inhibitors which stops Aβ peptide formation.

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin B (200 μg/mL)
  • Culture Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 APP FACS

FACS analysis of APP (GFP) on HEK293/Human APP (GFP) Stable Cell Line.
HEK293/Human APP (GFP) Stable Cell Line was red line, negative control HEK293 cells was grey line (QC tested).

Bioactivity-Bioactivity CELL BASE
 APP CELL

HEK293/Human APP (GFP) Stable Cell Line (Cat. No. CHEK-ATP081) was treated with β-secretase (BACE1) inhibitor and γ-Secretase inhibitor (DAPT) inhibitor, the process of amyloid precursor protein(APP) metabolism by endogenous secretase was inhibited, and the result is shown as fluorescent aggregation of APP-GFP. A. DMSO. B. 10 μm β-secretase (BACE1) inhibitor. C. 10 μM γ -secretase inhibitor (DAPT). D. 5 μm β-secretase (BACE1) inhibitor + 5 μM γ -secretase inhibitor (DAPT) (Routinely tested).

Please contact us if you are interested in related cell pool service.

  • Background
    Amyloid precursor protein (APP) is  a type I integral membrane protein ubiquitously expressed in many tissues and concentrated in the synapses of neurons. The majority of APP is cleaved at the plasma membrane by the α-secretase in the non-amyloidogenic pathway.  The amyloidogenic pathway starts with β-secretase cleavage by BACE1 on the N-terminal part of the Aβ domain, releasing sAPPβ from a membrane-anchored fragment named βCTF or C103, which is subsequently cleaved by γ-secretase to release Aβ.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

Comments (0)


Voraussichtlicher Liefertermin für vorrätige Produkte: 2 Arbeitstage

Price(EUR) : €3540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:11 Details
  • Number of Drugs in Clinical Trials:39 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Nachricht schicken